|
1
|
Schwarzer U, Sommer F, Klotz T, Braun M,
Reifenrath B and Engelmann U: The prevalence of Peyronie’s disease:
results of a large survey. BJU Int. 88:727–730. 2001.
|
|
2
|
Ralph D, Gonzalez-Cadavid N, Mirone V,
Perovic S, Sohn M, Usta M and Levine L: The management of
Peyronie’s disease: evidence-based 2010 guidelines. J Sex Med.
7:2359–2374. 2010.
|
|
3
|
Mulhall JP, Creech SD, Boorjian SA, Ghaly
S, Kim ED, Moty A, Davis R and Hellstrom W: Subjective and
objective analysis of the prevalence of Peyronie’s disease in a
population of men presenting for prostate cancer screening. J Urol.
171:2350–2353. 2004.PubMed/NCBI
|
|
4
|
Dean RC and Lue TF: Physiology of penile
erection and pathophysiology of erectile dysfunction. Urol Clin
North Am. 32:379–395. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gonzalez-Cadavid NF and Rajfer J:
Mechanisms of disease: new insights into the cellular and molecular
pathology of Peyronie’s disease. Nat Clin Pract Urol. 2:291–297.
2005.PubMed/NCBI
|
|
6
|
Haag SM, Hauck EW, Szardening-Kirchner C,
Diemer T, Cha ES, Weidner W and Eickelberg O: Alterations in the
transforming growth factor (TGF)-beta pathway as a potential factor
in the pathogenesis of Peyronie’s disease. Eur Urol. 51:255–261.
2007.PubMed/NCBI
|
|
7
|
Domes T, De Young L, O’Gorman DB, Gan BS,
Bella AJ and Brock G: Is there a role for proteomics in Peyronie’s
disease? J Sex Med. 4:867–877. 2007.PubMed/NCBI
|
|
8
|
El-Sakka AI, Hassoba HM, Chui RM,
Bhatnagar RS, Dahiya R and Lue TF: An animal model of
Peyronie’s-like condition associated with an increase of
transforming growth factor beta mRNA and protein expression. J
Urol. 158:2284–2290. 1997.
|
|
9
|
Assinder SJ, Dong Q, Kovacevic Z and
Richardson DR: The TGF-beta, PI3K/Akt and PTEN pathways:
established and proposed biochemical integration in prostate
cancer. Biochem J. 417:411–421. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Danielpour D: Functions and regulation of
transforming growth factor-beta (TGF-beta) in the prostate. Eur J
Cancer. 41:846–857. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cantley LC: The phosphoinositide 3-kinase
pathway. Science. 296:1655–1657. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Carracedo A and Pandolfi PP: The PTEN-PI3K
pathway: of feedbacks and cross-talks. Oncogene. 27:5527–5541.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Andre E, Gazzieri D, Bardella E, Ferreira
J, Mori MA, Saul VV, Bader M, Calixto JB, De Giorgio R, Corinaldesi
R, Geppetti P and Trevisani M: Expression and functional
pharmacology of the bradykinin B1 receptor in the normal and
inflamed human gallbladder. Gut. 57:628–633. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Reif S, Lang A, Lindquist JN, Yata Y,
Gabele E, Scanga A, Brenner DA and Rippe RA: The role of focal
adhesion kinase-phosphatidylinositol 3-kinase-akt signaling in
hepatic stellate cell proliferation and type I collagen expression.
J Biol Chem. 278:8083–8090. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gentilini A, Marra F, Gentilini P and
Pinzani M: Phosphatidylinositol-3 kinase and extracellular
signal-regulated kinase mediate the chemotactic and mitogenic
effects of insulin-like growth factor-I in human hepatic stellate
cells. J Hepatol. 32:227–234. 2000. View Article : Google Scholar
|
|
16
|
Kulik G, Klippel A and Weber MJ:
Antiapoptotic signalling by the insulin-like growth factor I
receptor, phosphatidylinositol 3-kinase, and Akt. Mol Cell Biol.
17:1595–1606. 1997.PubMed/NCBI
|
|
17
|
Kim AH, Khursigara G, Sun X, Franke TF and
Chao MV: Akt phosphorylates and negatively regulates apoptosis
signal-regulating kinase 1. Mol Cell Biol. 21:893–901. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Coffer PJ, Jin J and Woodgett JR: Protein
kinase B (c-Akt): a multifunctional mediator of
phosphatidylinositol 3-kinase activation. Biochem J. 335(Pt 1):
1–13. 1998.PubMed/NCBI
|
|
19
|
Lee H, Jung KH, Jeong Y, Hong S and Hong
SS: HS-173, a novel phosphatidylinositol 3-kinase (PI3K) inhibitor,
has anti-tumor activity through promoting apoptosis and inhibiting
angiogenesis. Cancer Lett. 328:152–159. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hong S, Lee S, Kim B, Lee H and Hong SS:
Discovery of new azaindole-based PI3Kalpha inhibitors: apoptotic
and antiangiogenic effect on cancer cells. Bioorg Med Chem Lett.
20:7212–7215. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Piao S, Choi MJ, Tumurbaatar M, Kim WJ,
Jin HR, Shin SH, Tuvshintur B, Yin GN, Song JS, Kwon MH, Lee SJ,
Han JY, Kim SJ, Ryu JK and Suh JK: Transforming growth factor
(TGF)-beta type I receptor kinase (ALK5) inhibitor alleviates
profibrotic TGF-beta1 responses in fibroblasts derived from
Peyronie’s plaque. J Sex Med. 7:3385–3395. 2010.PubMed/NCBI
|
|
22
|
LaRochelle JC and Levine LA: A survey of
primary-care physicians and urologists regarding Peyronie’s
disease. J Sex Med. 4:1167–1173. 2007.PubMed/NCBI
|
|
23
|
Sasso F, Gulino G, Falabella R, D’Addessi
A, Sacco E, D’Onofrio A and Bassi PF: Peyronie’s disease: lights
and shadows. Urol Int. 78:1–9. 2007.
|
|
24
|
Shindel AW and Lue TF: Peyronie’s disease:
past, present, future? Curr Urol Rep. 9:425–427. 2008.
|
|
25
|
Hauck EW, Diemer T, Schmelz HU and Weidner
W: A critical analysis of nonsurgical treatment of Peyronie’s
disease. Eur Urol. 49:987–997. 2006.PubMed/NCBI
|
|
26
|
Son G, Hines IN, Lindquist J, Schrum LW
and Rippe RA: Inhibition of phosphatidylinositol 3-kinase signaling
in hepatic stellate cells blocks the progression of hepatic
fibrosis. Hepatology. 50:1512–1523. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Conte E, Fruciano M, Fagone E, Gili E,
Caraci F, Iemmolo M, Crimi N and Vancheri C: Inhibition of PI3K
prevents the proliferation and differentiation of human lung
fibroblasts into myofibroblasts: the role of class I P110 isoforms.
PLoS One. 6:e246632011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Abdel-Hamid IA and Anis T: Peyronie’s
disease: perspectives on therapeutic targets. Expert Opin Ther
Targets. 15:913–929. 2011.
|
|
29
|
Bobustuc GC, Smith JS, Maddipatla S, Jeudy
S, Limaye A, Isley B, Caparas ML, Constantino SM, Shah N, Baker CH,
Srivenugopal KS, Baidas S and Konduri SD: MGMT inhibition restores
ERalpha functional sensitivity to antiestrogen therapy. Mol Med.
18:913–929. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Anderson MS, Shankey TV, Lubrano T and
Mulhall JP: Inhibition of Peyronie’s plaque fibroblast
proliferation by biologic agents. Int J Impot Res. 12(Suppl 3):
S25–S31. 2000.PubMed/NCBI
|
|
31
|
Mulhall JP, Nicholson B, Pierpaoli S,
Lubrano T and Shankey TV: Chromosomal instability is demonstrated
by fibroblasts derived from the tunica of men with Peyronie’s
disease. Int J Impot Res. 16:288–293. 2004.PubMed/NCBI
|
|
32
|
Elmore S: Apoptosis: a review of
programmed cell death. Toxicol Pathol. 35:495–516. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Mikulec AA, Hanasono MM, Lum J, Kadleck
JM, Kita M and Koch RJ: Effect of tamoxifen on transforming growth
factor beta1 production by keloid and fetal fibroblasts. Arch
Facial Plast Surg. 3:111–114. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
He Z, Gao Y, Deng Y, Li W, Chen Y, Xing S,
Zhao X, Ding J and Wang X: Lipopolysaccharide induces lung
fibroblast proliferation through Toll-like receptor 4 signaling and
the phosphoinositide3-kinase-Akt pathway. PLoS One. 7:e359262012.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Voloshenyuk TG, Landesman ES, Khoutorova
E, Hart AD and Gardner JD: Induction of cardiac fibroblast lysyl
oxidase by TGF-beta1 requires PI3K/Akt, Smad3, and MAPK signaling.
Cytokine. 55:90–97. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Xia H, Khalil W, Kahm J, Jessurun J,
Kleidon J and Henke CA: Pathologic caveolin-1 regulation of PTEN in
idiopathic pulmonary fibrosis. Am J Pathol. 176:2626–2637. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Marra F, Gentilini A, Pinzani M, Choudhury
GG, Parola M, Herbst H, Dianzani MU, Laffi G, Abboud HE and
Gentilini P: Phosphatidylinositol 3-kinase is required for
platelet-derived growth factor’s actions on hepatic stellate cells.
Gastroenterology. 112:1297–1306. 1997.
|
|
38
|
Foukas LC, Berenjeno IM, Gray A, Khwaja A
and Vanhaesebroeck B: Activity of any class IA PI3K isoform can
sustain cell proliferation and survival. Proc Natl Acad Sci USA.
107:11381–11386. 2010. View Article : Google Scholar : PubMed/NCBI
|
